Insider Selling: Thomas F. Ackerman Unloads 23,156 Shares of Charles River Laboratories Stock (CRL)
Charles River Laboratories (NYSE:CRL) CFO Thomas F. Ackerman unloaded 23,156 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $59.25, for a total transaction of $1,371,993.00. Following the transaction, the chief financial officer now directly owns 125,704 shares of the company’s stock, valued at approximately $7,447,962. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Charles River Laboratories in a research note on Wednesday, August 13th. They now have a $59.00 price target on the stock, up previously from $58.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Finally, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $58.00.
Charles River Laboratories (NYSE:CRL) opened at 59.50 on Thursday. Charles River Laboratories has a 52-week low of $44.12 and a 52-week high of $62.50. The stock has a 50-day moving average of $54.97 and a 200-day moving average of $56.08. The company has a market cap of $2.777 billion and a P/E ratio of 24.32.
Charles River Laboratories (NYSE:CRL) last announced its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 16.5% on a year-over-year basis. Analysts expect that Charles River Laboratories will post $3.33 EPS for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.